Predict your next investment

HEALTHCARE | Drug Development
immuron.com.au

See what CB Insights has to offer

Stage

IPO | IPO

Date of IPO

6/8/2017

Market Cap

0.04B

About Immuron

Immuron is a microbiome company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases. Immuron has a technology platform that enables a shorter development therapeutic cycle. The company markets and sells Travelan for the prevention of travellers' diarrhoea.

Immuron Headquarter Location

Building 10 25-37 Chapman Street

Blackburn North, Victoria, 3131,

Australia

+61 388924802

Latest Immuron News

AXA1125 safe, well tolerated up to 16 weeks in patients with NAFLD

Aug 17, 2021

Disclosures: Harrison reports being a stock shareholder in Akero, Cirius, Galectin, Genfit, HistoIndex, Madrigal, Metacrine, NGM Bio, and NorthSea; a consultant for Akero, Alentis, Altimmune, Axcella,Cirius, Chronic Liver Disease Foundation, CiVi BioPharma, CymaBay, Echosens, Fibronostics, Forsite Labs, Fortress Biotech, Galectin, Genfit, Gilead, Hepion, HighTide, HistoIndex, Intercept,Madrigal, Medpace, Metacrine, NGM Bio, NorthSea, Novartis, Novo Nordisk, Perspectum, Poxel, Prometic, Ridgeline Therapeutics, Sagimet, Terns and Viking receives grant/research support from Akero, Axcella, Bristol Myers Squibb, Cirius, CiVi Biopharma, Conatus, CymaBay, Enyo, Galectin, Galmed, Genentech, Genfit, Gilead, Hepion, High-Tide, Immuron, Intercept, Madrigal, Metacrine, NGM Bio, North- Sea, Novartis, Novo Nordisk, Pfizer, Sagimet, Second Genome, Tobira/Allergan, and Viking. Please see study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Among patients with nonalcoholic fatty liver disease, AXA1125 showed greater activity over 16 weeks compared with AXA1957 and placebo, according to a study published in The American Journal of Gastroenterology. “[Our] systematic characterization of specific [endogenous metabolic modulator (EMM)] compositions in NAFLD adds to the depth of knowledge on the safety and physiologic activity of EMMs and highlights that specificity of EMM composition matters for optimal effects,” Stephen A. Harrison, MD, from Pinnacle Clinical Research, San Antonio, Texas, and colleagues wrote. “Our findings support the potential of a novel EMM composition, AXA1125, to simultaneously address the multifactorial pathogenesis of NAFLD/[nonalcoholic steatohepatitis (NASH)], their key comorbidities, representing a unique modality with a coordinated multitargeted mechanism of action without major safety or tolerability issues. Future investigations are planned to assess the histological effects and longer term safety of AXA1125 in a double-blind, randomized, placebo-controlled, paired-biopsy trial over 48 weeks in individuals with biopsy-confirmed NASH.” Harrison and colleagues performed a multicenter, 16-week placebo-controlled, single-blind trial of 102 patients with NAFLD, of whom 40 had type 2 diabetes. Patients were randomly assigned to AXA1125 24 g, AXA1957 13.5 g or 20.3 g or placebo administered twice daily. Investigators assessed key metabolism (MRI-proton density fat fraction [MRI-PDFF] and homeostasis model assessment of insulin resistance [HOMA-IR]) and fibroinflammation markers (alanine aminotransferase [ALT], corrected T1 [cT1], keratin-18 [K-18] M65, and N-terminal type III collagen propeptide [Pro-C3]). Adverse events and standard laboratory evaluations were among the safety outcomes. “Baseline characteristics of the 102 enrolled subjects, including 40 with type 2 diabetes, were consistent with presumed nonalcoholic steatohepatitis,” Harrison and colleagues wrote. “AXA1125 showed consistently greater biologic activity than AXA1957 or placebo.” Investigators noted changes from baseline to week 16 with AXA1125 compared with placebo in MRI-PDFF (22.9% vs. 5.7%), HOMA-IR (4.4 vs. 0.7), ALT (21.9% vs. 7.2%), K-18 M65 (13.6% vs. 20.1%. ), (cT1 69.6 vs. 18.3) ms (P < .05), and Pro-C3 (13.6% vs. 3.6%). With AXA1957 20.3 g, changes from baseline to week 16 included MRI-PDFF 8.1%, HOMA-IR 8.4, ALT 20.7%, K-18 M65 6.6%, cT1 34.7 ms and Pro-C3 15.6%. According to researchers, there were more patients treated with AXA1125 that achieved clinically relevant thresholds including 30% MRI-PDFF or greater reductions at week 16, 17 IU/L or greater in ALT, and 80 ms cT1 or greater reductions. Products were both safe and well tolerated by patients with stable lipid and weight profiles, according to Harrison and colleagues. Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Immuron

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Immuron is included in 1 Expert Collection, including Microbiome.

M

Microbiome

274 items

Immuron Patents

Immuron has filed 4 patents.

The 3 most popular patent topics include:

  • Diseases of liver
  • Hepatology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/17/2014

12/4/2018

Clostridiaceae, Acetylcholinesterase inhibitors, Inflammations, Fluoroquinolone antibiotics, Bacterial diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/17/2014

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/4/2018

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clostridiaceae, Acetylcholinesterase inhibitors, Inflammations, Fluoroquinolone antibiotics, Bacterial diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Immuron Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Immuron Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.